Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 20/20 | 1.00 |
| ▸ | BACE2 | Q9Y5Z0 | 13/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.69 |
| ▸ | CTSD | P07339 | 1/20 | 0.69 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ly-2886721 SCHEMBL971344 | 1.00 | BACE1 (1.00) | BACE1BACE2KCNH2CTSDCYP2D6 | |
| Ly-2886721 SCHEMBL18195437 | 1.00 | BACE1 (1.00) | BACE1BACE2KCNH2CTSDCYP2D6 | |
| Ly-2886721 SCHEMBL30477100 | 1.00 | BACE1 (1.00) | BACE1BACE2KCNH2CTSDCYP2D6 | |
| Ly-2886721 SCHEMBL970474 | 0.99 | BACE1 (0.98) | BACE1BACE2KCNH2CTSDCYP2D6 | |
| Ly-2886721 SCHEMBL31235710 | 0.99 | BACE1 (0.98) | BACE1BACE2KCNH2CTSDCYP2D6 | |
| SCHEMBL2620122 | 0.93 | BACE1 (0.87) | BACE1BACE2KCNH2CTSDCYP2D6 | |
| SCHEMBL2932592 | 0.93 | BACE1 (0.87) | BACE1BACE2KCNH2CTSDCYP2D6 | |
| SCHEMBL3306806 | 0.91 | BACE1 (0.84) | BACE1BACE2KCNH2CTSDCYP2D6 | |
| SCHEMBL2620249 | 0.91 | BACE1 (0.84) | BACE1BACE2KCNH2CTSDCYP2D6 | |
| SCHEMBL2965834 | 0.91 | BACE1 (0.84) | BACE1BACE2KCNH2CTSDCYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180256720-A1 | COMPOSITIONS AND METHODS FOR TREATING HIV-ASSOCIATED NEUROCOGNITIVE DISORDERS | THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES (US) | 2018-09-13 | — | — | US | claimed |
| EP-2451793-B1 | BACE INHIBITORS | LILLY CO ELI (US) | 2016-11-02 | — | — | EP | claimed |
| US-8278441-B2 | BACE inhibitors | ELI LILLY AND COMPANY (US) | 2012-10-02 | — | — | US | claimed |
| US-20110009395-A1 | BACE INHIBITORS | ELI LILLY AND COMPANY (US) | 2011-01-13 | — | — | US | claimed |
| US-20230218629-A1 | THERAPEUTIC COMPOSITIONS AND METHODS FOR PREVENTION AND TREATMENT OF DIASTOLIC DYSFUNCTION | Ambetex Pty Ltd (AU) | 2023-07-13 | — | — | US | disclosed |
| US-20230218629-A1 | THERAPEUTIC COMPOSITIONS AND METHODS FOR PREVENTION AND TREATMENT OF DIASTOLIC DYSFUNCTION | Ambetex Pty Ltd (AU) | 2023-07-13 | — | — | US | disclosed |
| WO-2023073148-A1 | VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 3 AS BIOMARKER FOR BACE2 ACTIVITY | JANSSEN PHARMACEUTICA NV (BE) | 2023-05-04 | — | — | WO | disclosed |
| US-11559528-B2 | BACE1 inhibition for the treatment of cancer | THE CLEVELAND CLINIC FOUNDATION (US) | 2023-01-24 | — | — | US | disclosed |
| US-20210069205-A1 | BACE1 INHIBITION FOR THE TREATMENT OF CANCER | THE CLEVELAND CLINIC FOUNDATION | 2021-03-11 | — | — | US | disclosed |
| US-20180256720-A1 | COMPOSITIONS AND METHODS FOR TREATING HIV-ASSOCIATED NEUROCOGNITIVE DISORDERS | THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES (US) | 2018-09-13 | — | — | US | disclosed |
| EP-2451793-B1 | BACE INHIBITORS | LILLY CO ELI (US) | 2016-11-02 | — | — | EP | disclosed |
| EP-2451793-B1 | BACE INHIBITORS | LILLY CO ELI (US) | 2016-11-02 | — | — | EP | disclosed |
| US-20120323001-A1 | BACE INHIBITORS | ELI LILLY AND COMPANY (US) | 2012-12-20 | — | — | US | disclosed |
| US-8278441-B2 | BACE inhibitors | ELI LILLY AND COMPANY (US) | 2012-10-02 | — | — | US | disclosed |
| US-8278441-B2 | BACE inhibitors | ELI LILLY AND COMPANY (US) | 2012-10-02 | — | — | US | disclosed |
| US-20110009395-A1 | BACE INHIBITORS | ELI LILLY AND COMPANY (US) | 2011-01-13 | — | — | US | disclosed |
| US-20110009395-A1 | BACE INHIBITORS | ELI LILLY AND COMPANY (US) | 2011-01-13 | — | — | US | disclosed |
| WO-2011005738-A1 | BACE INHIBITORS | ELI LILLY AND COMPANY (US) | 2011-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11559528-B2 | BACE1 inhibition for the treatment of cancer | BACE1, BACE2, APP | BACE1 1/4885BACE2 2/4885KCNH2 4431/4885 |
| US-20120323001-A1 | BACE INHIBITORS | BACE1, BACE2, APP | BACE1 1/4885BACE2 2/4885KCNH2 3088/4885 |
| US-20210069205-A1 | BACE1 INHIBITION FOR THE TREATMENT OF CANCER | BACE1, BACE2, APP | BACE1 1/4885BACE2 2/4885KCNH2 4431/4885 |
| US-20110009395-A1 | BACE INHIBITORS | BACE1, BACE2, APP | BACE1 1/4885BACE2 2/4885KCNH2 3088/4885 |
| US-20230218629-A1 | THERAPEUTIC COMPOSITIONS AND METHODS FOR PREVENTION AND TREATMENT OF DIASTOLIC DYSFUNCTION | TNNI3, TNNT2, TNNC1 | BACE1 5/4885BACE2 12/4885KCNH2 2268/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.